TRUFF
Rhelion Life Sciences Corp.
OTC Markets OTCQBUSDEQUITY
Healthcare
DELAYED
Sell
-36/100
Last price
0.02
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.02
Day high
0.02
Day low
0.02
Volume
112.70K
Market cap
$12.28M
P/E (TTM)
—
52W range
0.01 – 0.04
Trailing performance
Returnvs SPY
1W
-4.76%
-6.3%
1M
-4.76%
-5.8%
3M
+11.11%
+8.1%
6M
-4.76%
-19.3%
YTD
+25.00%
+11.5%
1Y
-23.08%
-38.3%
3Y
-64.91%
-146.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TRUFF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
36.26M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 30, 26 | Nguyen (Thanh Tan Steven) Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) |
— | 0 | — | Direct |
| Apr 30, 26 | Nguyen (Thanh Tan Steven) Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) |
— | 0 | — | Indirect |
| Apr 29, 26 | Lightburn (Benjamin) Senior Officer of Issuer |
— | 0 | — | Direct |
| Apr 29, 26 | Ranken (Lisa) Senior Officer of Issuer |
— | 0 | — | Direct |
| Mar 20, 26 | Shapiro (Todd Michael) Director of Issuer |
BUY | 152.00K | $2.74K | Direct |
| Mar 18, 26 | Shapiro (Todd Michael) Director of Issuer |
BUY | 200.00K | $4.40K | Direct |
| Jan 26, 26 | Lamb (Brad) Director of Issuer |
EXERCISE | 500.00K | $7.50K | Direct |
| Jan 26, 26 | Shapiro (Todd Michael) Director of Issuer |
EXERCISE | 262.87K | $3.94K | Direct |
| Nov 11, 25 | Galloro (Michael Bernardino) Director of Issuer |
BUY | 1.11M | $27.71K | Indirect |
| Nov 11, 25 | Lamb (Brad) Director of Issuer |
BUY | 2.60M | $65.00K | Direct |
| Nov 11, 25 | Li (Ka Yin Keith) Senior Officer of Issuer |
— | 83.33K | — | Direct |
| Nov 11, 25 | Posen (Binyomin Yehuda) Director of Issuer |
BUY | 951.50K | $23.79K | Direct |
| Nov 11, 25 | Shapiro (Todd Michael) Director of Issuer |
— | 1.17M | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Galloro (Michael Bernardino) |
Director of Issuer | — | Acquisition or disposition under a prospectus exemption |
Lamb (Brad) |
Director of Issuer | 7.12M | Exercise of rights |
Li (Ka Yin Keith) |
Senior Officer of Issuer | 83.33K | Exercise of rights |
Lightburn (Benjamin) |
Senior Officer of Issuer | 3.44M | Opening Balance-Initial SEDI Report |
Nguyen (Thanh Tan Steven) |
Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | — | Opening Balance-Initial SEDI Report |
Posen (Binyomin Yehuda) |
Director of Issuer | 2.30M | Acquisition or disposition under a prospectus exemption |
Ranken (Lisa) |
Senior Officer of Issuer | 219.81K | Opening Balance-Initial SEDI Report |
Shapiro (Todd Michael) |
Director of Issuer | 15.45M | Acquisition or disposition in the public market |
Fundamentals
Market cap$12.28M
Enterprise value$4.99M
Revenue (TTM)$3.83M
Gross profit$1.61M
EBITDA$-4.33M
Net income$-6.43M
EPS (TTM)$-0.00
Free cash flow$-376.34K
Total cash$8.13M
Total debt$1.45M
Book value / share$0.02
Shares outstanding614.12M
Float575.17M
Short % of float—
Dividend yield0.00%
Beta (5Y)0.90
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book0.91
EV / revenue1.30
EV / EBITDA-1.15
Gross margin42.06%
Operating margin-774.51%
Profit margin-181.28%
Return on equity-41.31%
Return on assets-13.71%
Debt / equity8.02
Current ratio3.26
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.20M | $4.94M | $4.75M | $3.95M | -15.1% |
| Operating revenue | $4.20M | $4.94M | $4.75M | $3.95M | -15.1% |
| Cost of revenue | $2.60M | $3.03M | $2.73M | $2.24M | -14.1% |
| Gross profit | $1.59M | $1.91M | $2.02M | $1.71M | -16.8% |
| Research & development | $17.54K | $24.79K | $51.38K | $305.62K | -29.3% |
| Selling, general & admin | $5.34M | $5.48M | $7.22M | $5.93M | -2.6% |
| Total operating expense | $5.72M | $6.12M | $8.21M | $6.66M | -6.7% |
| Operating income | -$4.12M | -$4.21M | -$6.19M | -$4.95M | +2.0% |
| Net interest income | $201.84K | $203.96K | $271.81K | $152.92K | -1.0% |
| Pre-tax income | -$7.17M | -$4.42M | -$7.77M | -$5.96M | -62.4% |
| Tax provision | -$325.70K | -$107.23K | -$59.19K | -$159.50K | -203.7% |
| Net income | -$6.10M | -$4.04M | -$7.63M | -$5.40M | -51.0% |
| Net income to common | -$6.10M | -$4.04M | -$7.63M | -$5.40M | -51.0% |
| Basic EPS | -0.01 | -0.01 | -0.02 | -0.01 | -46.5% |
| Diluted EPS | -0.01 | -0.01 | -0.02 | -0.01 | -46.5% |
| EBIT | -$7.11M | -$4.13M | -$7.51M | -$5.90M | -72.2% |
| EBITDA | -$6.75M | -$3.35M | -$6.58M | -$5.27M | -101.4% |
| Basic shares | 416.59M | 401.11M | 395.21M | 373.11M | +3.9% |
| Diluted shares | 416.59M | 401.11M | 395.21M | 373.11M | +3.9% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $8.47M | $12.27M | $14.17M | $18.49M | -31.0% |
| Cash & short-term investments | $9.05M | $12.27M | $14.17M | $18.53M | -26.2% |
| Accounts receivable | $450.28K | $404.03K | $524.41K | $518.15K | +11.4% |
| Inventory | $846.13K | $1.00M | $874.26K | $741.25K | -15.5% |
| Total current assets | $12.46M | $14.74M | $17.07M | $22.21M | -15.5% |
| Property, plant & equipment | $1.52M | $5.68M | $5.66M | $5.39M | -73.3% |
| Goodwill & intangibles | $0 | $22.07K | $333.74K | $1.65M | -100.0% |
| Total assets | $14.57M | $21.22M | $24.08M | $30.14M | -31.3% |
| Total current liabilities | $3.13M | $3.26M | $3.12M | $2.68M | -4.0% |
| Current debt | $1.13M | $1.78M | $1.30M | $1.16M | -36.3% |
| Total debt | $1.42M | $2.18M | $1.72M | $1.77M | -35.0% |
| Total liabilities | $3.35M | $3.87M | $3.82M | $3.80M | -13.5% |
| Retained earnings | -$48.30M | -$42.20M | -$38.16M | -$30.53M | -14.5% |
| Shareholder equity | $11.97M | $17.35M | $20.07M | $26.06M | -31.0% |
| Working capital | $9.33M | $11.48M | $13.95M | $19.52M | -18.7% |
| Net tangible assets | $11.97M | $17.33M | $19.74M | $24.41M | -31.0% |
| Shares issued | 425.71M | 410.85M | 393.79M | 387.89M | +3.6% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$6.84M | -$4.31M | -$7.71M | -$5.80M | -58.9% |
| Depreciation & amortisation | $358.10K | $777.12K | $931.21K | $630.04K | -53.9% |
| Stock-based compensation | $575.76K | $576.31K | $1.41M | $563.52K | -0.1% |
| Change in working capital | $487.79K | $1.25M | $124.97K | -$676.36K | -60.9% |
| Operating cash flow | -$2.42M | -$1.48M | -$3.23M | -$4.39M | -63.3% |
| Capital expenditure | -$1.23M | -$531.22K | -$693.81K | -$2.06M | -130.9% |
| Investing cash flow | -$1.23M | -$525.40K | -$650.43K | -$3.17M | -133.4% |
| Share buybacks | — | $0 | -$88.81K | $0 | — |
| Financing cash flow | -$766.03K | $445.17K | -$206.95K | -$114.16K | -272.1% |
| Free cash flow | -$3.65M | -$2.01M | -$3.92M | -$6.45M | -81.1% |
| End cash position | $8.47M | $12.84M | $14.37M | $18.49M | -34.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $186.07K | $875.32K | $1.26M | $754.08K | $553.03K | -78.7% |
| Operating revenue | $186.07K | $875.32K | $1.26M | $754.08K | $553.03K | -78.7% |
| Cost of revenue | $16.33K | $416.75K | $906.88K | $426.79K | $402.50K | -96.1% |
| Gross profit | $169.74K | $458.57K | $357.92K | $327.29K | $150.53K | -63.0% |
| Research & development | $84.12K | $6.50K | $8.17K | $2.87K | $0 | +1,193.4% |
| Selling, general & admin | $1.39M | $1.16M | $1.46M | $1.22M | $1.32M | +20.1% |
| Total operating expense | $1.57M | $1.25M | $1.56M | $1.32M | $1.41M | +26.2% |
| Operating income | -$1.40M | -$787.51K | -$1.20M | -$996.24K | -$1.26M | -78.1% |
| Net interest income | $33.32K | $35.89K | $39.62K | $53.51K | $72.83K | -7.1% |
| Pre-tax income | -$1.50M | -$3.43M | -$1.44M | -$1.23M | -$1.18M | +56.3% |
| Tax provision | $0 | -$234.41K | -$28.61K | -$41.66K | -$21.03K | +100.0% |
| Net income | -$1.87M | -$2.53M | -$1.38M | -$1.17M | -$1.03M | +26.2% |
| Net income to common | -$1.87M | -$2.53M | -$1.38M | -$1.17M | -$1.03M | +26.2% |
| Basic EPS | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Diluted EPS | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| EBIT | -$1.49M | -$3.42M | -$1.43M | -$1.22M | -$1.17M | +56.5% |
| EBITDA | -$1.39M | -$3.34M | -$1.34M | -$1.11M | -$1.08M | +58.5% |
| Basic shares | 551.45M | — | 417.59M | 412.25M | 411.87M | — |
| Diluted shares | 551.45M | — | 417.59M | 412.25M | 411.87M | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.60M | $8.47M | $9.24M | $10.23M | $11.45M | -69.3% |
| Cash & short-term investments | $8.13M | $9.05M | $9.88M | $10.73M | $11.67M | -10.2% |
| Accounts receivable | $396.93K | $450.28K | $814.26K | $502.11K | $473.56K | -11.8% |
| Inventory | $381.37K | $846.13K | $943.41K | $1.03M | $1.02M | -54.9% |
| Total current assets | $11.09M | $12.46M | $14.29M | $14.93M | $15.86M | -11.0% |
| Property, plant & equipment | $1.81M | $1.52M | $3.24M | $3.41M | $3.49M | +19.3% |
| Goodwill & intangibles | $7.12M | $0 | $0 | $5.79K | $13.93K | — |
| Total assets | $21.86M | $14.57M | $18.20M | $19.02M | $20.14M | +50.0% |
| Total current liabilities | $3.41M | $3.13M | $3.14M | $2.88M | $2.84M | +9.0% |
| Current debt | $1.16M | $1.13M | $1.31M | $1.13M | $1.13M | +2.2% |
| Total debt | $1.45M | $1.42M | $1.61M | $1.51M | $1.53M | +1.9% |
| Total liabilities | $3.82M | $3.35M | $3.58M | $3.41M | $3.41M | +14.2% |
| Retained earnings | -$50.17M | -$48.30M | -$45.77M | -$44.39M | -$43.23M | -3.9% |
| Shareholder equity | $18.81M | $11.97M | $14.69M | $15.66M | $16.75M | +57.2% |
| Working capital | $7.68M | $9.33M | $11.16M | $12.05M | $13.03M | -17.7% |
| Net tangible assets | $11.68M | $11.97M | $14.69M | $15.65M | $16.73M | -2.4% |
| Shares issued | 614.12M | 425.71M | 422.53M | 412.25M | 412.25M | +44.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$1.50M | -$3.20M | -$1.41M | -$1.07M | -$1.16M | — | +53.1% |
| Depreciation & amortisation | $101.14K | $79.55K | $85.13K | $102.74K | $90.68K | — | +27.1% |
| Stock-based compensation | $194.08K | -$196.23K | $348.62K | $43.98K | $379.39K | — | +198.9% |
| Change in working capital | $294.94K | $368.70K | -$88.01K | -$71.18K | $278.28K | — | -20.0% |
| Operating cash flow | -$889.06K | -$460.94K | -$800.85K | -$756.67K | -$403.07K | — | -92.9% |
| Capital expenditure | — | -$1.09M | -$3.22K | -$2.57K | -$132.09K | -$39.26K | — |
| Investing cash flow | -$4.77M | -$102.32K | -$316.58K | -$465.33K | -$342.09K | — | -4,562.3% |
| Share buybacks | — | — | — | — | — | $0 | — |
| Financing cash flow | -$30.65K | -$202.28K | $151.48K | -$33.84K | -$681.38K | — | +84.8% |
| Free cash flow | -$889.06K | -$1.55M | -$804.07K | -$759.24K | -$535.17K | — | +42.6% |
| End cash position | $2.60M | $8.47M | $9.24M | $10.23M | $11.45M | — | -69.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders5.90%
Held by institutions0.00%
Institutions holding0
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.02
-8.68% from price
SMA 20
0.02
-11.31% from price
SMA 50
0.02
-10.39% from price
SMA 100
0.02
-15.33% from price
SMA 200
0.02
-4.24% from price
EMA 12
0.02
-7.30% from price
EMA 26
0.02
-9.64% from price
EMA 50
0.02
-10.83% from price
RSI (14)
43.6
Neutral
MACD (12,26,9)
-0.00
Hist -0.00
ATR (14)
0.00
15.71% of price
Realised vol 30D
135.6%
Annualised
Bollinger upper
0.03
20, 2σ
Bollinger lower
0.02
20, 2σ
50 / 200 cross
Golden
0.02 vs 0.02
Trend bias
Below 200
-4.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.83
Less volatile than market
Correlation to SPY
-0.07
Largely independent
Realised vol 30D
135.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-60.7%
Peak to trough
Max drawdown 5Y
-93.9%
Peak to trough
ATR 14
0.00
15.71% of price
Beta (reported)
0.90
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1071:1000
Split dateSep 22, 2017
Headlines
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
TMX Newsfile · 8d ago
Rhelion Life Sciences Unit Expands Supply Agreement with University of Chieti-Pescara for PEX010
MT Newswires · 12d ago
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
TMX Newsfile · 12d ago
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate
TMX Newsfile · 15d ago
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
TMX Newsfile · 16d ago
Rhelion Life Sciences' Unit Signs Supply and Licensing Agreement With Centre for Human Drug Research
MT Newswires · 20d ago
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
TMX Newsfile · 20d ago
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy
TMX Newsfile · 22d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.